Immix Biopharma Investor Presentation Deck slide image

Immix Biopharma Investor Presentation Deck

3 Optimal Tumor Binding While Ensuring High Expression COBRA Binder COBRA Binder Leads with Heavy Chain Proven Linker of Heavy and Light Chain Employed .. IHSL VH (GGGGS)5 LSH VL (GGGGS) 5 Biomarker Research VL |-- VH 3.6 Source:: Moreno-Cortes E,. et al Front Oncol. 2023; Mazinani M, et al. Biomark Res. 2022. 1.6 Day 10 CAR-T Expansion (10^7) HSL LSH 80 76 Specific Cytotoxicity (%): JeKo1 (ROR1+) co-culture HSL LSH doi: 10.3389/fonc.2023.1200914 "Glycine (Gly) and serine (Ser) residues provide the flexibility necessary for antigen-binding sites to change conformation and maintain good stability in aqueous solutions... prevent[ing] formation of secondary structures and reduc[ing] likelihood of the linker interfering with the folding and function of the scFv" September 19, 2022 doi: 10.1186/s40364-022-00417-w ● ●●● IMMIX S BIOPHARMA NXC-201 COBRA Binder: Heavy Chain - Proven Linker - Light Chain Configuration, enabling: Rapid, Sustained CAR- T Expansion ✓ Improved Cytotoxicity in the presence of antigen 13
View entire presentation